Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RBM and Psynova to co-develop schizophrenia diagnostic test
Rules-Based Medicine (RBM) and Psynova will focus on the unmet clinical need for an objective and reliable diagnostic test to accelerate and optimize the treatment of schizophrenia. Under
Rules-Based Medicine (RBM) and Psynova will focus on the unmet clinical need for an objective and reliable diagnostic test to accelerate and optimize the treatment of schizophrenia. Under
The Phase IIb proof-of-concept program consists of two clinical trials – a six-month trial evaluating PRX-03140 in combination with donepezil that began earlier this month and this three-month
Pursuant to the non-binding letter of intent, the company will acquire all of the issued and outstanding shares of Prologue for $13 million, consisting of $4.5 million in
The insulin-like growth factor-1 (IGF-1) receptor is said to be a promising target for treatment of cancer, since the IGF-1 receptor is crucial for the survival and growth
In the course of the study 13 patients were treated at a glaucoma center in Mexico City, under the supervision of Felix Gil Carrasco, an eye surgeon. IOPtima
The decision was made based on the results of an analysis for futility conducted by the independent data monitoring committee. Due to an observed lower mortality than anticipated
Smith & Nephew Endoscopy and John Hayhurst sued Arthrex over three years ago, claiming that Arthrex’s Bio Suture Tak, Peek Suture Tak and Push Lock suture anchors infringed
The patent covers certain uses of satraplatin related to the treatment of a cancer or tumor resistant or refractory to a taxane, including docetaxel (Taxotere) and paclitaxel (Taxol).
The company reported blinded disease-free survival data for those patients that have completed 36 months of follow-up subsequent to randomization in both the treatment and control arms, with
Joint R&D work is beginning with the Bayer subsidiary Icon Genetics on a novel production approach. Antigens are to be produced for the first time in tobacco plants